Browse by Research Project Code

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0

Tarafdar, A. et al. (2017) CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood, 129(2), pp. 199-208. (doi: 10.1182/blood-2016-09-742049) (PMID:27793879) (PMCID:PMC5305055)

Scott, M. T. et al. (2016) Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition. Cancer Discovery, 6(11), pp. 1248-1257. (doi: 10.1158/2159-8290.CD-16-0263) (PMID:27630125) (PMCID:PMC6538532)

Gallipoli, P., Cook, A., Rhodes, S. , Hopcroft, L. , Wheadon, H. , Whetton, A. D., Jorgensen, H. G. , Bhatia, R. and Holyoake, T. L. (2014) JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of chronic phase CML CD34+ cells in vitro and in vivo. Blood, 124(9), pp. 1492-1501. (doi: 10.1182/blood-2013-12-545640) (PMID:24957147) (PMCID:PMC4148771)

Gallipoli, P., Pellicano, F., Morrison, H., Laidlaw, K., Allan, E.K., Bhatia, R., Copland, M. , Jorgensen, H.G. and Holyoake, T.L. (2013) Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation. Blood, 122(19), pp. 3335-3339. (doi: 10.1182/blood-2013-02-485607) (PMID:24041577) (PMCID:PMC3953090)

Shah, M., Gallipoli, P., Lyons, J., Holyoake, T. L. and Jorgensen, H. (2012) Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro. Blood Cells, Molecules, and Diseases, 48(3), pp. 199-201. (doi: 10.1016/j.bcmd.2012.01.005)

Gallipoli, P., Shepherd, P., Irvine, D., Drummond, M. and Holyoake, T. (2011) Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study. British Journal of Haematology, 155(1), pp. 128-130. (doi: 10.1111/j.1365-2141.2011.08653.x)

Gallipoli, P., Abraham, S. A. and Holyoake, T. L. (2011) Hurdles toward a cure for CML: the CML stem cell. Hematology/Oncology Clinics of North America, 25(5), pp. 951-966. (doi: 10.1016/j.hoc.2011.09.001)

This list was generated on Fri Mar 29 09:38:36 2024 GMT.